Gilead Sciences Cash Flow Statement
GILD / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Gilead Sciences generated $10.0B in operating cash flow and $9.5B in free cash flow in FY2025. Free cash flow margin was 32.1% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $8.5B | $480.0M | $6.2B | $123.0M | $5.4B | $123.0M | $4.6B | $13.5B | $18.1B | $12.1B | $18.1B | $2.6B | $3.1B | $2.6B | $2.8B |
| Depreciation & Amortization | $370.0M | - | $329.0M | $288.0M | $255.0M | - | $233.0M | $177.0M | $161.0M | $125.0M | - | $83.0M | - | - | - |
| Operating Cash Flow | $10.0B | $10.8B | $11.4B | $8.2B | $9.1B | $8.2B | $11.9B | $17.0B | $21.3B | $12.8B | $21.3B | $3.2B | $3.1B | $3.2B | $3.6B |
| Capital Expenditures | $563.0M | $523.0M | $579.0M | $650.0M | $825.0M | $650.0M | $590.0M | $748.0M | $747.0M | $557.0M | $747.0M | $397.0M | $134.0M | $397.0M | $131.9M |
| Free Cash Flow | $9.5B | $10.3B | $10.8B | $7.5B | $8.3B | $7.5B | $11.3B | $16.3B | $20.5B | $12.3B | $20.5B | $2.8B | $3.0B | $2.8B | $3.5B |
| Share Buybacks | $1.9B | $1.1B | $546.0M | $1.6B | $1.7B | $1.6B | $954.0M | $11.0B | $10.0B | $5.3B | $10.0B | $667.0M | $582.0M | $667.0M | $2.4B |
| Dividends Paid | $4.0B | $3.9B | $3.6B | $3.4B | $3.2B | $3.4B | $2.7B | $2.5B | $1.9B | $0 | $1.9B | - | $0 | - | - |
| FCF Margin | 32.1% | 35.8% | 39.6% | 30.4% | 37.1% | 30.4% | 43.3% | 53.6% | 62.8% | 49.3% | 62.8% | 28.8% | 26.5% | 122.6% | 41.8% |